JP2022517865A - Ｃｘｃｌ１機能に関与する疾患の治療のための組成物および方法 - Google Patents

Ｃｘｃｌ１機能に関与する疾患の治療のための組成物および方法 Download PDF

Info

Publication number
JP2022517865A
JP2022517865A JP2021543528A JP2021543528A JP2022517865A JP 2022517865 A JP2022517865 A JP 2022517865A JP 2021543528 A JP2021543528 A JP 2021543528A JP 2021543528 A JP2021543528 A JP 2021543528A JP 2022517865 A JP2022517865 A JP 2022517865A
Authority
JP
Japan
Prior art keywords
antibody
cxcl1
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517865A5 (enExample
Inventor
ジェイ ロッサ― チャールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2022517865A publication Critical patent/JP2022517865A/ja
Publication of JP2022517865A5 publication Critical patent/JP2022517865A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7014—(Neo)vascularisation - Angiogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021543528A 2019-01-28 2020-01-28 Ｃｘｃｌ１機能に関与する疾患の治療のための組成物および方法 Pending JP2022517865A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797573P 2019-01-28 2019-01-28
US62/797,573 2019-01-28
PCT/US2020/015457 WO2020160022A1 (en) 2019-01-28 2020-01-28 Compositions and methods for treatment of diseases involving cxcl1 function

Publications (2)

Publication Number Publication Date
JP2022517865A true JP2022517865A (ja) 2022-03-10
JP2022517865A5 JP2022517865A5 (enExample) 2023-02-03

Family

ID=71841416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543528A Pending JP2022517865A (ja) 2019-01-28 2020-01-28 Ｃｘｃｌ１機能に関与する疾患の治療のための組成物および方法

Country Status (6)

Country Link
US (3) US11292832B2 (enExample)
EP (1) EP3917949A4 (enExample)
JP (1) JP2022517865A (enExample)
CN (1) CN113544143A (enExample)
CA (1) CA3127943A1 (enExample)
WO (1) WO2020160022A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471057A4 (en) * 2022-01-27 2026-03-04 Chiome Bioscience Inc ANTI-CXCL1 HUMAN ANTIBODY
WO2026060413A1 (en) * 2024-09-16 2026-03-19 Calgent Biotechnology Co., Ltd. Single chain antibodies and use thereof
CN120795145A (zh) * 2025-07-22 2025-10-17 青岛大学 一种抗cxcl1的纳米抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026895A1 (ja) * 2005-09-02 2007-03-08 Toray Industries, Inc. 尿路上皮ガンの検出用キットおよび方法
CN101261275A (zh) * 2008-01-23 2008-09-10 李力 一种用于早期卵巢癌诊断的检测试剂盒
WO2010050554A1 (ja) * 2008-10-31 2010-05-06 東レ株式会社 ヒトｃｘｃｌ１タンパク質の免疫学的測定方法
JP2016506720A (ja) * 2013-01-21 2016-03-07 アッヴィ・インコーポレイテッド 炎症性疾患のための抗ｔｎｆ及び抗ｉｌ１７併用治療薬バイオマーカー
JP2016528170A (ja) * 2013-05-17 2016-09-15 セントル ナショナル デ ラ ルシュルシュ サイエンティフィーク（シーエヌアールエス） 抗ｃｘｃｌ１抗体、抗ｃｘｃｌ７抗体および抗ｃｘｃｌ８抗体ならびにそれらの用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
CN102203177A (zh) 2008-10-29 2011-09-28 日本瑞翁株式会社 腈共聚物胶乳组合物和腈共聚物橡胶组合物
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9290570B2 (en) 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
US11267881B2 (en) * 2017-09-14 2022-03-08 Charles ROSSER Compositions and methods for treatment of diseases involving CXCL1 function
US11603569B2 (en) * 2018-03-20 2023-03-14 Cedars-Sinai Medical Center Immune modulating genes for prognosis, diagnosis and treatment of metastatic disease, and drug identification methods thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026895A1 (ja) * 2005-09-02 2007-03-08 Toray Industries, Inc. 尿路上皮ガンの検出用キットおよび方法
CN101261275A (zh) * 2008-01-23 2008-09-10 李力 一种用于早期卵巢癌诊断的检测试剂盒
WO2010050554A1 (ja) * 2008-10-31 2010-05-06 東レ株式会社 ヒトｃｘｃｌ１タンパク質の免疫学的測定方法
JP2016506720A (ja) * 2013-01-21 2016-03-07 アッヴィ・インコーポレイテッド 炎症性疾患のための抗ｔｎｆ及び抗ｉｌ１７併用治療薬バイオマーカー
JP2016528170A (ja) * 2013-05-17 2016-09-15 セントル ナショナル デ ラ ルシュルシュ サイエンティフィーク（シーエヌアールエス） 抗ｃｘｃｌ１抗体、抗ｃｘｃｌ７抗体および抗ｃｘｃｌ８抗体ならびにそれらの用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THERANOSTICS, vol. 9, no. 3, JPN6024003851, 2019, pages 853 - 867, ISSN: 0005399943 *

Also Published As

Publication number Publication date
US20220267430A1 (en) 2022-08-25
US20210301007A1 (en) 2021-09-30
US11292832B2 (en) 2022-04-05
US11760796B2 (en) 2023-09-19
WO2020160022A1 (en) 2020-08-06
CN113544143A (zh) 2021-10-22
EP3917949A4 (en) 2022-11-23
US20240018229A1 (en) 2024-01-18
EP3917949A1 (en) 2021-12-08
CA3127943A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
JP7057843B2 (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
TWI402078B (zh) 抗ｃｓｆ－１ｒ抗體
RU2568051C2 (ru) АНТИТЕЛА К ErbB3
JP2020531048A (ja) 結合剤
US20240018229A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
US12227583B2 (en) Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
CN110382532B (zh) 抗g-csf抗体及其用途
JP7458567B2 (ja) Ｃ－ｍｅｔ結合剤
EP3556771B1 (en) Anti-claudin 5 antibody, and medicine containing said antibody
EP3602060B1 (en) Compositions and methods for treating lung cancer
US20220169714A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
JPWO2016039402A1 (ja) 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体
JP7460183B2 (ja) 抗炭酸脱水酵素ｉｘ抗体
AU2014412643B2 (en) Novel EGFRvIII antibody and composition comprising same
KR101854529B1 (ko) 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
TWI869344B (zh) 抗-碳酸酐酶ix抗體
WO2025172588A1 (en) Bispecific constructs directed against fap and ltbr
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
JP2018508193A (ja) メディンを認識する抗体
TW202436359A (zh) 抗-碳酸酐酶ix抗體
HK40045557A (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
HK40005045B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TW201827070A (zh) 合成多肽、含該多肽的組合物、由其產生的抗體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240826